Asensus Surgical, Inc. (2TX.F)
| Previous Close | 0.2204 |
| Open | 0.2206 |
| Bid | 0.2242 x N/A |
| Ask | 0.2408 x N/A |
| Day's Range | 0.2206 - 0.2230 |
| 52 Week Range | 0.1830 - 0.6100 |
| Volume | |
| Avg. Volume | 4,986 |
| Market Cap | 62.594M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2900 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
GlobeNewswireAsensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery Program
Second System to be Utilized by one of the Largest Private Hospital Systems in Japan RESEARCH TRIANGLE PARK, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced that Sendai Tokushukai Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System. "We're happy that Sendai Tokushukai Hospital has initiated a lease on the Senh
GlobeNewswireAsensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG
KARL STORZ to provide up to $20 million in bridge financingRESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient, today announced that it has entered into a non-binding letter of intent (the “letter of intent”) with KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company (“KARL STORZ”) to
- GlobeNewswire
Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023
RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced its operating and financial results for the fourth quarter and full year 2023. Full Year Highlights Completed in vivo evaluation of the LUNA™ Surgical System by nine independent surgeons through thirteen procedures across gynecology, urology, and general surgeryOver 3,550 surgical pr
